| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28c49f5fac5dd076915fc4b618b4459f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e5f8850fd7a2d0780195ebe6791d3b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53c694a85e76b0fc6962f3b6d3abe88d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7014 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2012-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cf4c4d82d16fa8f02af0f8a7f8a9d9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c13fe48b5daec9bfbda7168930b9062a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0616c527298316b862cf31f03a930d1 |
| publicationDate |
2012-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012118969-A2 |
| titleOfInvention |
Method of selecting cancer patients for anti-angiogenesis therapy in combination with chemotherapy |
| abstract |
What is described is a method for identifying a cancer patient that is amenable to anti- angiogenesis therapy in combination with chemotherapy by measuring the status of tumor cell HER2 expression, p53 expression, and apoptosis or endothelial cell CD31 expression in a tumor sample from the patient. Bevacizumab, an antibody to vascular endothelial growth factor, is a preferred anti-angiogenesis therapy for treating several cancer types including breast cancer. Cancer patients with p53-negative or HER2 negative tumors, or tumors with low levels of apoptosis or high endothelial cell CD31 expression in the tumor vasculature are more amenable to anti-angiogenesis therapy with bevacizumab. These tumor characteristics provide a diagnostic method for identifying cancer patients amendable to anti-angiogenesis therapy plus chemotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016077227-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104991065-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017226198-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107106688-A |
| priorityDate |
2011-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |